Supernus Pharmaceuticals, Inc. (SUPN)
49.43
-1.77
(-3.46%)
USD |
NASDAQ |
May 15, 16:00
49.35
-0.08
(-0.16%)
After-Hours: 20:00
Supernus Pharmaceuticals Research and Development Expense (Quarterly) : 38.94M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 66.26M |
| Johnson & Johnson | 3.495B |
| Amphastar Pharmaceuticals, Inc. | 22.90M |
| Assertio Holdings, Inc. | 0.454M |
| Eli Lilly & Co. | 3.51B |